The Legal Examiner Mark The Legal Examiner Mark The Legal Examiner Mark search twitter facebook feed linkedin instagram google-plus avvo phone envelope checkmark mail-reply spinner error close
Skip to main content

Until Eli Lilly abruptly pulled patients off of prasugrel, the blood thinning drug had been one of the more promising drugs for the large pharmaceutical company. A. Michael Lincoff, director of cardiovascular research at the Cleveland Clinic, was quoted in the Wall St. Journal as stating that in all likelihood the drug trial was suspended for safety reasons with bleeding the most likely safety factor. Lilly still plans to submit prasugrel to the FDA for approval by the end of this year.

For more information on this subject, please refer to the section on Drugs, Medical Devices, and Implants.

Comments are closed.

Of Interest